Top

Published in:

01-11-2008 | Letter to the Editor

The double deceit generated by an insertion mechanism in chronic myeloid leukemia with t(9;9;22)

Authors: Francesco Albano, Antonella Zagaria, Luisa Anelli, Alessandra Pannunzio, Floriana Manodoro, Nicoletta Coccaro, Antonella Russo Rossi, Vincenzo Liso, Mariano Rocchi, Giorgina Specchia

Published in: Annals of Hematology | Issue 11/2008

Excerpt

Dear Editor, …

Johansson B, Fioretos T, Mitelman F (2002) Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol 107:76–94PubMedCrossRef

Mitelman Database of Chromosome Aberrations in Cancer (2007) Mitelman F, Johansson B and Mertens F (Eds.), http://cgap.nci.nih.gov/Chromosomes/Mitelman

Sessarego M, Fugazza G, Bruzzone R, Ballestrero A, Miglino M, Bacigalupo A (2000) Complex chromosome rearrangements may locate the bcr/abl fusion gene sites other than 22q11. Haematologica 85:35–39PubMed

Zagaria A, Anelli L, Albano F, Storlazzi CT, Liso A, Roberti MG, Buquicchio C, Liso V, Rocchi M, Specchia G (2004) A fluorescence in situ hybridization study of complex t(9;22) in two chronic myelocytic leukemia cases with a masked Philadelphia chromosome. Cancer Genet Cytogenet 150:81–85PubMedCrossRef

Fitzgerald PH, Morris CM (1991) Complex chromosomal translocations in the Philadelphia chromosome leukemias: serial translocations or a concerted genomic rearrangement. Cancer Genet Cytogenet 57:143–151PubMedCrossRef

Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, Apperley J, Cervantes F, Cortes J, Deininger M, Gratwohl A, Guilhot F, Horowitz M, Hughes T, Kantarjian H, Larson R, Niederwieser D, Silver R, Hehlmann R, European LeukemiaNet (2006) Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 108:1809–1820PubMedCrossRef

Lichter P, Tang Chang CJ, Call K, Hermanson G, Evans GA, Housman D, Ward DC (1990) High resolution mapping of human chromosomes 11 by in situ hybridization with cosmid clones. Science 247:64–69PubMedCrossRef

Storlazzi CT, Specchia G, Anelli L, Albano F, Pastore D, Zagaria A, Rocchi M, Liso V (2002) Breakpoint characterization of der(9) deletions in CML patients. Genes Chromosomes Cancer 35:271–276PubMedCrossRef

Albano F, Anelli L, Zagaria A, Archidiacono N, Liso V, Specchia G, Rocchi M (2007) “Homebrew” FISH assay shows higher efficiency than BCR-ABL dual color, dual fusion probe in detecting microdeletions and complex rearrangements associated with t(9;22) in chronic myeloid leukemia. Cancer Genet Cytogenet 174:121–126PubMedCrossRef

10.

Pfaffl MW, Horgan GW, Dempfle L (2002) Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 30:e36PubMedCrossRef

11.

Michalova K, Zemanova Z, Bkezinova J, Moravcova J, Oltova A, Sobotka J, Kuglik P, Kozak T, Sindelarova L, Jankovska M, Obomilova A, Sieglova Z, Polak J, Nadvornikova S, Haskovec C (2002) Location of the BCR/ABL fusion genes on both chromosomes 9q34 in Ph negative chronic myeloid leukemia. Leuk Lymphoma 43:1695–1700PubMedCrossRef

12.

Lim TH, Tien SL, Lim P, Lim AS (2005) The incidence and patterns of BCR/ABL rearrangements in chronic myeloid leukaemia (CML) using fluorescence in situ hybridisation (FISH). Ann Acad Med Singapore 34:533–538PubMed

13.

Haigh S, Cuthbert G (2004) Fluorescence in situ hybridization characterization of different cryptic BCR-ABL rearrangements in chronic myeloid leukemia. Cancer Genet Cytogenet 155:132–137PubMedCrossRef

Title: The double deceit generated by an insertion mechanism in chronic myeloid leukemia with t(9;9;22)
Authors: Francesco Albano
Antonella Zagaria
Luisa Anelli
Alessandra Pannunzio
Floriana Manodoro
Nicoletta Coccaro
Antonella Russo Rossi
Vincenzo Liso
Mariano Rocchi
Giorgina Specchia
Publication date: 01-11-2008
Publisher: Springer-Verlag
Published in: Annals of Hematology / Issue 11/2008
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-008-0511-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 11/2008

Effective screening for double heterozygosity of Hb E/α0-thalassemia

Farnesyl transferase inhibitor (lonafarnib) in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia: a phase II study

Neuroophthalmological side effects following intrathecal administration of liposomal cytarabine for central nervous system prophylaxis in three adolescents with acute myeloid leukaemia

Familial occurrence of sequential B-cell lymphoma and myeloproliferative disease

Vitamin D receptor genotypes and response to zoledronic acid therapy in thalassemia-induced osteoporosis

Fat emboli unleashed: an exceptional etiology of encephalitis in sickle cell disease

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials